ロード中...
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase. However, a substantial number of patients are either primarily refractory or acquire resistance to imatinib. While a number of...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Informa Healthcare
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2430171/ https://ncbi.nlm.nih.gov/pubmed/18203007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701713689 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|